BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 29, 2025
Home » Authors » Amanda Pedersen

Amanda Pedersen

Articles

ARTICLES

BioVentrix reports first-in-man use of Revivent-TC system

Oct. 2, 2013
By Amanda Pedersen

Survey reveals lengthy delay in neurological diagnosis

Oct. 1, 2013
By Amanda Pedersen

FDA approves MiniMed 530G artificial pancreas system

Sep. 30, 2013
By Amanda Pedersen
The FDA has approved a first-generation artificial pancreas system from Medtronic (Minneapolis), the company reported on Friday. The MiniMed 530G with Enlite artificial pancreas system with Threshold Suspend automation is designed for people with diabetes. Medtronic noted that the system is the first in the U.S. that can automatically stop insulin delivery when sensor glucose values reach a preset level and when the patient doesn`t respond to the Threshold Suspend alarm.
Read More

Deals roundup: Stryker pays roughly $1.65B to acquire MAKO Surgical

Sep. 26, 2013
By Amanda Pedersen

FDA revises Sapien labeling, expanding patient population

Sep. 25, 2013
By Amanda Pedersen

Medtronic finds AdaptivCRT lowers risk of atrial fibrillation

Sep. 24, 2013
By Amanda Pedersen
Medtronic (Minneapolis) reported clinical trial results showing that heart failure patients treated with its exclusive AdaptivCRT feature experienced a nearly 50% reduction in atrial fibrillation (AF) risk. Pioneered by Medtronic, the AdaptivCRT technology is a feature on certain cardiac resynchronization therapy-defibrillators (CRT-Ds) designed to continually adjust therapy to a patient's natural heart rhythms and minimizes the amount of unnecessary right ventricular (RV) pacing. The results were presented Monday as a late breaking clinical trial at the Heart Failure Society of America's 17th annual scientific meeting in Orlando, Florida.
Read More

Healthcare survey finds 88% will pursue M&A next year

Sep. 23, 2013
By Amanda Pedersen

Agilent Technologies to split into two public companies

Sep. 20, 2013
By Amanda Pedersen

More to chiropractic care than expected

Sep. 19, 2013
By Amanda Pedersen
Until recently I, like most people, was under the misconception that chiropractic care was for people who have been involved in an accident or suffer from chronic neck or back pain. And, like most people, I never considered going to a chiropractor until I had a reason to. I first went to see Dr. Dean Jacks at Chiropractic Associates in Niceville, Florida, in July when I began having pain in my neck and upper back. Having never been to a chiropractor before, I really wasn’t sure what to expect....
Read More

RainDance has PCR platform validated in consortium paper

Sep. 18, 2013
By Amanda Pedersen
View All Articles by Amanda Pedersen

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 29, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 29, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing